Baiotec: Recently received a milestone payment of 5.4 million dollars from Intas.

Baiotai announcement: On February 10, 2025, the company signed an authorization licensing and commercialization agreement with Intas Pharmaceuticals Ltd. The exclusive commercialization rights of BAT2506 injection in the US market were licensed to Intas for a fee. Recently received a $5.4 million milestone payment from Intas, deducting $600,000 for corporate income tax, and the actual amount received is 38.3584 million yuan. This payment will further replenish the company's cash reserves and provide support for future pipeline research and internationalization strategies.